- 1、本文档共92页,可阅读全部内容。
- 2、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
* Symbicort improves HRQL (SGRQ total score) SGRQ and SF 36 were used in both studies, but the data presented here are from the SGRQ, as recommended in the CPMP guidelines. The presentation is limited to the total scores, since this is the basis for assessment of clincial relevance, where a reduction of 4 is considered as a clinically relevant positive change.1 The change seen in the Symbicort group significantly exceeded the level which is clinically noticeable to the patient. Reference 1. PW Jones. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002;19(3): 398-404. * The first patient was enrolled on November 8th 2012, and the last patient completed the study on February 28th 2014. After assessing the eligibility during a 14-day run in period, patients were randomized (1:1) to receive either IND/GLY 110/50 μg once daily delivered via the Breezhaler? device (Novartis Pharma AG, Stein, Switzerland) or SFC 50/500 μg twice daily delivered via the Accuhaler? device (Glaxo Operations UK, Ware, UK) and matching placebos. The patients were treated in the morning (08:00 and 11:00 hours from both the devices) and evening (approximately 12 hours after the morning dose, Accuhaler? device only). Reference Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2015 (In press ) * n, number of patients; FEV1, forced expiratory volume in one second; SFC, salmeterol/fluticasone. At Week 26, IND/GLY was deemed to be non-inferior to SFC by meeting the pre-defined non-inferiority margin of -60 mL in trough FEV1 (treatment difference (Δ) = 72 mL, 95% CI: 40, 104) for the per protocol set. IND/GLY treatment demonstrated statistically significant superiority to SFC for trough FEV1 (Δ = 75 mL, 95% CI: 44, 107; P0.001)
您可能关注的文档
- 医学交流课件:中国慢性呼吸疾病防治工作现状及对策.pptx
- 医学交流课件:中国慢阻肺患者门诊管理的思考.pptx
- 医学交流课件:中国慢阻肺诊断现状挑战与应对.pptx
- 妇产科学课件:正常分娩(5年制理论课).pdf
- 口腔学课件:口腔颌面部感染.pdf
- 口腔学课件:口腔黏膜常见疾病.pdf
- 口腔学课件:牙龈牙周疾病.pdf
- 医学交流课件:AECOPD的表型与临床治疗.ppt
- 医学交流课件:Management of Preschool Wheeze.ppt
- 医学交流课件:变应性鼻炎病理过程中的最轻炎性反应及其临床意义.ppt
- 2024春八年级历史下册第二单元社会主义制度的建立与社会主义建设的探索第5课三大改造精炼新人教版.doc
- 2024_2025学年新教材高中地理第二章岩石圈与地表形态单元素养练含解析湘教版必修1.doc
- 精品解析:2022-2023学年河南省郑州市中牟县人教版三年级下册期中测试数学试卷(解析版).docx
- 2024年高中语文第13课宇宙的边疆课时作业2含解析新人教版必修3.doc
- 2024_2025学年高中物理第1章电磁感应与现代生活1电磁感应__划时代的发现精练含解析沪教版选修3_2.doc
- 2024_2025学年高中语文课后作业7李清照词两首含解析新人教版必修4.doc
- 精品解析:2023-2024学年河南省郑州市高新区人教版三年级下册期末考试数学试卷(解析版).docx
- 2024年中考生物重点专题突破专题五生物圈中的人训练新人教版.doc
- 2024_2025学年高中地理第四章人类与地理环境的协调发展2人地关系思想的演变练习含解析湘教版必修2.doc
- 2024_2025学年高中化学第3章重要的有机化合物第3节饮食中的有机化合物第2课时乙酸练习含解析鲁科版必修2.doc
最近下载
- 小学体育《侧手翻》优质教案教学设计.pdf
- 双列圆锥滚子轴承型号对照表.pdf
- 错牙合畸形的多学科联合治疗(课前预习).pptx
- 专题06文学类文本阅读-解析版-2022-2023学年九年级上学期语文期末真题分类汇编(北京专用).docx VIP
- 中国工商银行财务风险分析.doc VIP
- 造价咨询服务方案进度计划安排及保证措施.docx VIP
- 心内科重点专科汇报教学材料.ppt
- 完善开发区审核公告目录修订工作的思考.pdf
- 9.2《三位数乘两位数、除数是两位数的除法》(教案)人教版四年级上册数学.docx VIP
- 9.2《三位数乘两位数、除数是两位数的除法》(教案)-四年级上册数学人教版.docx VIP
文档评论(0)